Evidence-Based Treatment and Management of Low-Grade UTUC With Novel Therapies
Webcast
0.25 AMA PRA Category 1 Credit™ ...OVERVIEW
Evidence-Based Treatment and Management of Low-Grade UTUC With Novel Therapies is organized by Prime Education, LLC and will be held from Aug 30, 2024 - Aug 29, 2025.
Release Date: August 30, 2024
Expiration Date: August 29, 2025
Description:
Staying current with the most recent advancements in the treatment for upper tract urothelial carcinoma (UTUC) is essential for your practice.
Participate in this dynamic Clinical Case Challenge to enhance your understanding of the latest real-world evidence concerning novel therapies for low-grade UTUC (LG-UTUC). This engaging activity guides you in therapy selection and sequencing and adverse event management for a patient with UTUC. You can also compare your knowledge and decision-making skills with those of your peers!
After completing the activity, be sure to download a concise summary of the key evidence that supports these practices.
Learning Objectives:
- Differentiate available therapies for UTUC based on safety and efficacy data, routes of administration, and indications
- Evaluate new and emerging real-world and clinical trial data on novel therapies for low-grade (LG) upper tract urothelial carcinoma (UTUC) across a variety of patient types
- Design guideline-adherent, individualized treatment plans for patients with UTUC, including strategies for adverse event management
Additional details will be posted as soon as information is available.
ACCREDITATION & CREDITS
Accreditation:
Joint Accreditation Statement
In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation Statement
PRIME® designates this Enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Physician Assistant Accreditation Statement
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioner Accreditation Statement
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.25 contact hour (which includes 0.25 hour of pharmacology).
Pharmacist Accreditation Statement
This Knowledge-based activity has been approved for 0.25 contact hour (0 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-24-209-H01-P . Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service (help@nabp.pharmacy).
Nurse Accreditation Statement
PRIME® designates this activity for 0.25 contact hour.
TARGET AUDIENCE
NursingPharmacistOncologistsUrologistsNursesNurse PractitionersMedical OncologistsSPECIALITIES
UrologyOncologyRELATED ONLINE COURSES
Quick Links